AlphAIAlphAI — Financial news for AI agents
247wallst.comOCT 51 min read

TRex Bio (TRXB) sets $14 to $16 range for its $125 million Nasdaq IPO

TRex Bio (TRXB) plans a $125M IPO on Nasdaq, pricing between $14-16 per share. The company focuses on regulatory T cell therapies. J.P. Morgan and Evercore ISI lead the underwriting, indicating institutional interest.

Original reporting
247wallst.com
Published Oct 5, 2026, 10:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 12:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
TRex Bio (TRXB) sets $14 to $16 range for its $125 million Nasdaq IPO — source image
Source · 247wallst.com
Decision brief

The 30-second read

Med
01

Why it matters

The disclosed pricing range sets the market's first valuation benchmark; investor demand will be gauged by the final price within the $14‑$16 band.

02

Market read

First disclosure of a biotech IPO pricing range; relevant for short‑term traders and longer‑term biotech investors.

03

What to watch

Regulatory approval timelines for T‑reg therapies and competition from larger immunotherapy players could affect post‑IPO performance.

Relevance 7/10Novelty 7/10Timing: pricing expected within days

Background

TRex Bio is a clinical‑stage biotech developing regulatory T‑cell therapies, a niche but increasingly watched area of immunology.

Market effects

Sector

Adds another biotech IPO to a crowded pipeline, may influence investor allocation to early‑stage cell‑therapy stocks.

Regional

Nasdaq listing adds a small‑cap biotech to the US market, modest effect on overall market breadth.

Global

Limited to biotech investors; no broader macro impact.

Counterpoint

What could challenge this read

If the IPO is priced at the low end, the stock could underperform initial expectations, offering a short opportunity.

Key entities

  • company
    TRex Bio, Inc.

    Biotech firm pursuing T‑reg cell therapies and filing for a Nasdaq IPO.

  • financial_institution
    J.P. Morgan

    Lead underwriter for the IPO.

  • financial_institution
    Evercore ISI

    Co‑lead underwriter for the IPO.

Read at source← All news

Related articles

OCT 5
High

Immunology startup TRex Bio sets price range for $133 million public debut

TRex Bio Inc., a biotech firm developing autoimmune treatments, aims to raise $133.3M in an IPO, offering 8.33M shares at $14-$16 each. The company's lead candidate, TRB-061, is in Phase 1b trials for atopic dermatitis, with data expected in mid-2027. Backed by investors like Eli Lilly and Pfizer Ventures, TRex Bio plans to use proceeds for clinical development and operations. It will list on Nasdaq under 'TRXB'.

investing.com2 min
SEP 18
MedAI 8/10

Trex Bio files for Nasdaq IPO; Eli Lilly eyes 19.9% stake

Trex Bio filed for a Nasdaq IPO under the ticker TRXB, with Eli Lilly planning to acquire up to 19.9% stake. The company's pipeline includes TRB-071 and TRB-051, with Eli Lilly partnering on the latter. Underwriters include J.P. Morgan, Evercore ISI, and others. The IPO aims to raise capital and establish a strategic partnership with Eli Lilly.

scanx.trade3 min
SEP 14
$TREXMed

Trex at Goldman Sachs conference: demand, growth plan lift outlook

Trex Company (TREX) raised its full-year 2026 net sales guidance to mid single-digit growth from low single-digit, citing stronger demand and operational improvements. The company expects about $1.25 billion in revenue by year-end 2026 and reaffirmed its long-term goal of $2 billion in revenue by 2030. Management highlighted growth from lower-priced products, a faster ramp at its new Little Rock plant, and strategic distribution changes.

investing.com2 min
AUG 11
$TREXMedAI 8/10

Trex (TREX) Q2 2026 Earnings Call Transcript

Trex Company (TREX) reported Q2 2026 net sales of $418 million, up 8%, with gross margin at 37.9% (down from 40.8%). Adjusted diluted EPS was $0.62 and adjusted EBITDA $112 million. Full-year 2026 guidance: net sales $1.215B to $1.25B, adjusted EBITDA $335M to $350M. The company authorized $150M more buybacks and accelerated its Little Rock facility ramp-up.

fool.com6 min